Novartis presents 2021 ESMO Breast Cancer coverage

The presenters consider the clinical implications of molecular classification in breast cancer, review the recent evidence of CDK4/6 inhibitors in molecular subtypes and discuss how molecular subtyping may change the practice and future of breast cancer treatment. The sessions and content covered were independently chosen by the HCPs. The content discussed is the thoughts of HCP and not necessarily that of Novartis.

ESMO Slides for Monaleesa 2 presentation

View the Overall Survival Results from the Phase lll MONALEESA-2 Trial

Click here ⟶

Ambassador program

Canadian Breast Cancer experts from across the country came together to curate the latest data from ESMO 2021, with a focus on how these data may impact clinical practice.
Disclaimer: The content for this program was independently developed by the program steering committee, who are solely responsible for this content, including any information on unapproved use(s) of a product. Novartis Pharmaceuticals Canada Inc. has provided only financial and/or logistical support for this educational activity.

ESMO 2021 Key Congress Highlights for Breast Cancer

Click here ⟶

Les faits saillants du congrès ESMO 2021 sur le cancer du sein

Cliquez ici ⟶

Global Medical Expert Videos

View expert opinion on the overall survival results from the phase III MONALEESA-2 trial of postmenopausal patients with HR+/HER2− advanced breast cancer treated with endocrine therapy ± ribociclib.

The opinions expressed in these videos are those of the speakers and not necessarily attributable to Novartis Pharmaceuticals Canada Inc. Furthermore, the data under discussion in this piece is not present in the approved Product Monograph

MLR ID 123442

OncoCorner - Novartis Canada Medical Education

The content on this platform was independently developed by Canadian HCPs who are solely responsible for this content, including any information on unapproved use(s) of a product.
Novartis Pharmaceuticals Canada Inc. has provided only financial and/or logistical support for this platform. Users of this platform assume all responsibility for their use of any content owned by third parties as obtained from the platform.

Novartis presents 2021 ASCO Breast Cancer coverage

The presenters consider the clinical implications of molecular classification in breast cancer, review the recent evidence of CDK4/6 inhibitors in molecular subtypes and discuss how molecular subtyping may change the practice and future of breast cancer treatment. The sessions and content covered were independently chosen by the HCPs. The content discussed is the thoughts of HCP and not necessarily that of Novartis.

 

Dr Slamon Updated overall survival (OS) results from the Phase III MONALEESA 3 trial of postmenopausal patients (pts) with HR+/HER2 advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

 

Dr Chia - Updated overall survival (OS) results from the Phase III MONALEESA 3 trial of postmenopausal patients (pts) with HR+/HER2 advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

 

Dr Slamon Author Commentary with Dr Slamon : Updated overall survival results from the Phase III MONALEESA 3 trial of postmenopausal patients with HR+/HER2 advanced breast cancer treated with fulvestrant (FUL) ± ribociclib (RIB)

 

Dr Chia and Dr Rugo Impact of Duration of Prior Cyclin Dependent Kinase 4/6 Inhibitor Therapy on Alpelisib Benefit in Patients with Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-), PIK3CA-Mutated Advanced Breast Cancer (ABC) from BYLieve

169390 - 145896
×

Medical Information Request

×

Ask Speakers